SCHEMBL17243302

SCHEMBL17243302

Cn1c(=O)n(C(C)(C)C)c(=O)c2ccc(F)cc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.49
HPD P32754 2/20 0.38
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
ADORA2A P29274 1/20 0.36
PGR P06401 1/20 0.36
AR P10275 1/20 0.36
GRM4 Q14833 3/20 0.36
ERCC1 P07992 1/20 0.35
FEN1 P39748 1/20 0.35
ERCC4 Q92889 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PKM P14618 2/20 0.34
HTT P42858 1/20 0.34
MEN1 O00255 1/20 0.33
HCRTR1 O43613 1/20 0.33
KMT2A Q03164 1/20 0.33
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17825042 0.82 ATM (0.56) ATMMAOAMAOBADORA2ATSHR
SCHEMBL22745870 0.81 EGLN1 (0.44) ATMHPDMAOAMAOBPGR
SCHEMBL22745940 0.72 HPD (0.40) ATMHPDMAOAMAOBERCC1
SCHEMBL31189206 0.72 HPD (0.40) ATMHPDMAOAMAOBERCC1
SCHEMBL22016239 0.72 ADORA3 (0.43) HPDADORA2APGRGRM4ERCC1
SCHEMBL18270526 0.71 ATM (0.63) ATMHSD17B10MEN1HCRTR1KMT2A
SCHEMBL13355033 0.70 SMN1; SMN2 (0.55) ATMMAOAMAOBADORA2AHSD17B10
SCHEMBL31650745 0.70 SMN1; SMN2 (0.55) ATMMAOAMAOBADORA2AHSD17B10
SCHEMBL86061 0.69 ATM (0.77) ATMHSD17B10PKMMEN1HCRTR1
SCHEMBL17241490 0.69 P2RX3 (0.46) TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170137387-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES ORION CORPORATION (FI) 2017-05-18 US disclosed
EP-3140301-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES Orion Corporation (FI) 2017-03-15 EP disclosed
WO-2015169999-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES ORION CORPORATION (FI) 2015-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137387-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES GABRB1, GABRB3, GABRB2 ATM 3619/4885HPD 4334/4885MAOA 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.